{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:28:52Z","timestamp":1648546132152},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.toxlet.2012.05.019","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T10:33:50Z","timestamp":1338374030000},"page":"298-306","source":"Crossref","is-referenced-by-count":2,"title":["Repeated intravenous infusion of human apolipoprotein(a) kringle V is associated with reversible dose-dependent acute tubulointerstitial nephritis without affecting glomerular filtration function"],"prefix":"10.1016","volume":"212","author":[{"given":"Ho-Jeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Kyung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hyung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Keun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeup","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2012.05.019_bib0005","first-page":"10487","article-title":"International Conference on Harmonisation; guidance on S9 nonclinical evaluation for anticancer pharmaceuticals; availability","volume":"75","author":"Anon.","year":"2010","journal-title":"Federal Register Notice"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0010","first-page":"4025","article-title":"Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study","volume":"9","author":"Beerepoot","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathologica et Microbiologica Scandinavica"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0020","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","article-title":"Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo","volume":"270","author":"Callow","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1568011023353705","article-title":"Kringle structures and antiangiogenesis","volume":"2","author":"Cao","year":"2002","journal-title":"Current Medicinal Chemistry \u2013 Anticancer Agents"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nbt.1622","article-title":"Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt.1625","article-title":"Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/0-387-24361-5_8","article-title":"Angiostatin","volume":"126","author":"Doll","year":"2005","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-2275(20)41215-5","article-title":"Lipoprotein[a] in the chimpanezee: relationship of apo[a] phenotype to elevated plasma Lp[a] levels","volume":"35","author":"Doucet","year":"1994","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0055","first-page":"1388","article-title":"Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies","volume":"60","author":"Eberhard","year":"2000","journal-title":"Cancer Research"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.ph.51.030189.000315","article-title":"Cellular events in renal hypertrophy","volume":"51","author":"Fine","year":"1989","journal-title":"Annual Review of Physiology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0065","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1016\/S0021-9258(19)84439-3","article-title":"Physicochemical properties of apolipoprotein(a) and lipoprotein(a\u2212) derived from the dissociation of human plasma lipoprotein (a)","volume":"261","author":"Fless","year":"1986","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0070","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nature Medicine"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00666033","article-title":"The influence of angiogenesis research on management of patients with breast cancer","volume":"36","author":"Folkman","year":"1995","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/prot.340120212","article-title":"A structural assessment of the apo[a] protein of human lipoprotein[a]","volume":"12","author":"Guevara","year":"1992","journal-title":"Proteins"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/096032719501400312","article-title":"Guideline limit volumes for dosing animals in the preclinical stage of safety evaluation. Toxicology Subcommittee of the Association of the British Pharmaceutical Industry","volume":"14","author":"Hull","year":"1995","journal-title":"Human and Experimental Toxicology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0095","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/ndt\/gfm199","article-title":"Interstitial nephritis in a patient taking sorafenib","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0105","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1271\/bbb.70.916","article-title":"Crystallization of antiangiogenic Kringle V derived from human apolipoprotein A: crystallization applied to purification and formulation","volume":"70","author":"Kang","year":"2006","journal-title":"Bioscience, Biotechnology, and Biochemistry"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0110","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1097\/HJH.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects","volume":"27","author":"Kappers","year":"2009","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.amjopharm.2007.12.011","article-title":"Allergic interstitial nephritis possibly related to sunitinib use","volume":"5","author":"Khurana","year":"2007","journal-title":"American Journal of Geriatric Pharmacotherapy"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0120","doi-asserted-by":"crossref","first-page":"29000","DOI":"10.1074\/jbc.M301042200","article-title":"Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a)","volume":"278","author":"Kim","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2003.11.148","article-title":"Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases","volume":"313","author":"Kim","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000472175","article-title":"Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random","volume":"4","author":"Kraft","year":"1996","journal-title":"European Journal of Human Genetics"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0135","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0022-2275(20)38452-2","article-title":"Lipoprotein[a] is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus)","volume":"29","author":"Laplaud","year":"1988","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0140","doi-asserted-by":"crossref","first-page":"24004","DOI":"10.1074\/jbc.270.41.24004","article-title":"The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a)","volume":"270","author":"Lawn","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1593\/neo.12380","article-title":"Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model","volume":"14","author":"Lee","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0150","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jbiotec.2006.05.011","article-title":"Disruption of hexokinase II (HXK2) partly relieves glucose repression to enhance production of human kringle fragment in gratuitous recombinant Saccharomyces cerevisiae","volume":"126","author":"Lee","year":"2006","journal-title":"Journal of Biotechnology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0160","doi-asserted-by":"crossref","first-page":"F145","DOI":"10.1152\/ajprenal.90430.2008","article-title":"Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism","volume":"296","author":"Mu","year":"2009","journal-title":"American Journal of Physiology \u2013 Renal Physiology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O\u2019Reilly","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nbt.1627","article-title":"A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function","volume":"28","author":"Ozer","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-5793(84)80473-1","article-title":"Kringles: modules specialized for protein binding: homology of the gelatin-binding region of fibronectin with the kringle structures of proteases","volume":"171","author":"Patthy","year":"1984","journal-title":"FEBS Letters"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0005-2760(86)90120-7","article-title":"Characterization of an unusual lipoprotein similar to human lipoprotein a isolated from the baboon, Papio sp","volume":"877","author":"Rainwater","year":"1986","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0185","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/ajkd.2001.26889","article-title":"Renal handling of human apolipoprotein(a) and its fragments in the rat","volume":"38","author":"Reblin","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nbt.1634","article-title":"Towards consensus practices to qualify safety biomarkers for use in early drug development","volume":"28","author":"Sistare","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0195","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1016\/S0021-9258(18)83643-2","article-title":"Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis","volume":"264","author":"Tomlinson","year":"1989","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0200","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1623","article-title":"Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies","volume":"28","author":"Vaidya","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.toxlet.2012.05.019_bib0210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nbt.1624","article-title":"Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury","volume":"28","author":"Yu","year":"2010","journal-title":"Nature Biotechnology"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427412011447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427412011447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T13:08:53Z","timestamp":1642338533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427412011447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0378427412011447"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2012.05.019","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}